Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Panagiotis Koliou, Vasilios Karavasilis, Maria Theochari, Seth M Pollack, Robin L Jones & Khin Thway. (2018) Advances in the treatment of soft tissue sarcoma: focus on eribulin. Cancer Management and Research 10, pages 207-216.
Read now
Read now
Geraldine O'Sullivan Coyne, Janice Walshe & Catherine M Kelly. (2012) Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer. Expert Opinion on Drug Safety 11:4, pages 643-650.
Read now
Read now
Articles from other publishers (20)
Alessia Bono, Gabriele La Monica, Federica Alamia, Francesco Mingoia, Carla Gentile, Daniele Peri, Antonino Lauria & Annamaria Martorana. (2023) In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents. International Journal of Molecular Sciences 24:18, pages 13769.
Crossref
Crossref
Laura Fernández-Peña, Carlos Díez-Poza, Paula González-Andrés & Asunción Barbero. (2022) The Tetrahydrofuran Motif in Polyketide Marine Drugs. Marine Drugs 20:2, pages 120.
Crossref
Crossref
Galal H. Elgemeie & Reham A. Mohamed-Ezzat. 2022. New Strategies Targeting Cancer Metabolism. New Strategies Targeting Cancer Metabolism
507
546
.
C. De Angelis, D. Bruzzese, A. Bernardo, E. Baldini, L. Leo, A. Fabi, T. Gamucci, P. De Placido, F. Poggio, S. Russo, V. Forestieri, R. Lauria, I. De Santo, A. Michelotti, L. Del Mastro, M. De Laurentiis, M. Giuliano, S. De Placido & G. Arpino. (2021) Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). ESMO Open 6:2, pages 100054.
Crossref
Crossref
Claudia Pellacani & Georgios Eleftheriou. (2020) Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies. Advances in Medical Sciences 65:2, pages 265-285.
Crossref
Crossref
Harika Atmaca Ilhan & Çisil Çamlı Pulat. 2020. Encyclopedia of Marine Biotechnology. Encyclopedia of Marine Biotechnology
2529
2584
.
Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcom A. Smith & Peter J. Houghton. (2020) Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. Clinical Cancer Research 26:12, pages 3012-3023.
Crossref
Crossref
Kentaro Miyake, Takashi Murakami, Tasuku Kiyuna, Kentaro Igarashi, Kei Kawaguchi, Yunfeng Li, Arun S. Singh, Sarah M. Dry, Mark A. Eckardt, Yukihiko Hiroshima, Masashi Momiyama, Ryusei Matsuyama, Takashi Chishima, Itaru Endo, Fritz C. Eilber & Robert M. Hoffman. (2017)
Eribulin regresses a doxorubicin‐resistant Ewing's sarcoma with a
FUS‐ERG
fusion and
CDKN2A‐
deletion in a patient‐derived orthotopic xenograft (PDOX) nude mouse model
. Journal of Cellular Biochemistry 119:1, pages 967-972.
Crossref
Crossref
Antony Joseph. 2017. Investigating Seafloors and Oceans. Investigating Seafloors and Oceans
493
554
.
Kalimuthu Senthilkumar, Govindan Ramajayam, Jayachandran Venkatesan, Se-Kwon Kim & Byeong-Cheol Ahn. 2016. Marine Sponges: Chemicobiological and Biomedical Applications. Marine Sponges: Chemicobiological and Biomedical Applications
305
314
.
Frederick O. Stephens & Karl Reinhard AignerFrederick O. Stephens & Karl Reinhard Aigner. 2016. Basics of Oncology. Basics of Oncology
147
209
.
Nicholas F. Dybdal-Hargreaves, April L. Risinger & Susan L. Mooberry. (2015) Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent. Clinical Cancer Research 21:11, pages 2445-2452.
Crossref
Crossref
Ajai Prakash Gupta, Pankaj Pandotra, Manoj Kushwaha, Saima Khan, Rajni Sharma & Suphla Gupta. 2015.
341
445
.
Carmine De Angelis, Monica Milano, Brigida Stanzione, Piera Gargiulo, Sabino De Placido & Grazia Arpino. (2013) Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. Combination Products in Therapy 3:1-2, pages 25-37.
Crossref
Crossref
Kalimuthu Senthilkumar, Jayachandran Venkatesan, Panchanathan Manivasagan & Se-Kwon Kim. (2013) Antiangiogenic effects of marine sponge derived compounds on cancer. Environmental Toxicology and Pharmacology 36:3, pages 1097-1108.
Crossref
Crossref
Javier Cortes & Maria Vidal. (2011) Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Research and Treatment 133:3, pages 821-830.
Crossref
Crossref
Anne-Charlotte Dubbelman, Hilde Rosing, Robert S. Jansen, Marja Mergui-Roelvink, Alwin D. R. Huitema, Barbara Koetz, Margarita Lymboura, Larisa Reyderman, Arturo Lopez-Anaya, Jan H. M. Schellens & Jos H. Beijnen. (2012)
Mass Balance Study of [
14
C]Eribulin in Patients with Advanced Solid Tumors
. Drug Metabolism and Disposition 40:2, pages 313-321.
Crossref
Crossref
Krystyna M. Wozniak, Kenichi Nomoto, Rena G. Lapidus, Ying Wu, Valentina Carozzi, Guido Cavaletti, Kazuhiro Hayakawa, Satoru Hosokawa, Murray J. Towle, Bruce A. Littlefield & Barbara S. Slusher. (2011) Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. Cancer Research 71:11, pages 3952-3962.
Crossref
Crossref
Maurizio Callari, Vera Cappelletti, Loris De Cecco, Valeria Musella, Patrizia Miodini, Silvia Veneroni, Manuela Gariboldi, Marco Alessandro Pierotti & Maria Grazia Daidone. (2010) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment 127:3, pages 601-610.
Crossref
Crossref
Konstanty Wierzba, Makoto Muroi & Hiroyuki Osada. (2011) Proteomics accelerating the identification of the target molecule of bioactive small molecules. Current Opinion in Chemical Biology 15:1, pages 57-65.
Crossref
Crossref